KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Astrazeneca (AZN) over the last 7 years, with Q4 2025 value amounting to $9.0 million.

  • Astrazeneca's Change in Acquisitions & Divestments rose 12432.43% to $9.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $131.0 million, marking a year-over-year increase of 33666.67%. This contributed to the annual value of $131.0 million for FY2025, which is 33666.67% up from last year.
  • As of Q4 2025, Astrazeneca's Change in Acquisitions & Divestments stood at $9.0 million, which was up 12432.43% from $7.0 million recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Change in Acquisitions & Divestments registered a high of $114.0 million during Q2 2025, and its lowest value of -$57.0 million during Q1 2024.
  • Its 5-year average for Change in Acquisitions & Divestments is $22.2 million, with a median of $9.0 million in 2023.
  • Per our database at Business Quant, Astrazeneca's Change in Acquisitions & Divestments soared by 77500.0% in 2023 and then plummeted by 73333.33% in 2024.
  • Over the past 5 years, Astrazeneca's Change in Acquisitions & Divestments (Quarter) stood at -$24.0 million in 2021, then skyrocketed by 50.0% to -$12.0 million in 2022, then surged by 775.0% to $81.0 million in 2023, then tumbled by 145.68% to -$37.0 million in 2024, then soared by 124.32% to $9.0 million in 2025.
  • Its last three reported values are $9.0 million in Q4 2025, $7.0 million for Q3 2025, and $114.0 million during Q2 2025.